Loading…
Damora Therapeutics Inc Is A Biotechnology Company That Aims To Fundamentally Redefine Care For People With Hematologic Disorders. The Group Is Advancing A New Generation Of Biologics To Treat Mutant Calreticulin-Driven Myeloproliferative Neoplasms, Including Essential Thrombocythemia And Myelofibrosis, Where There Is Cruicial Medical Need For Disease-Modifying Treatments. Its Goal Is To Rapidly Bring Forward Optimized Therapies With Broad Mutation Coverage And Exceptional Convenience To Dramatically Improve Patient Outcomes. The Group'S Pipeline Products Are Dmr-001, Dmr-002, Dmr-003, And Gb3226.